期刊
ONCOGENE
卷 40, 期 7, 页码 1205-1216出版社
SPRINGERNATURE
DOI: 10.1038/s41388-020-01598-0
关键词
-
资金
- Universita della Svizzera italiana
Targeting the androgen receptor signaling axis has long been the main strategy for prostate cancer therapy, but stronger inhibition has led to a subset of cancers becoming AR-negative, with a poorer prognosis.
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据